Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ane Ogbe, … , Teresa Lambe, John Frater
Ane Ogbe, … , Teresa Lambe, John Frater
Published February 22, 2022
Citation Information: JCI Insight. 2022;7(7):e157031. https://doi.org/10.1172/jci.insight.157031.
View: Text | PDF
Research Article AIDS/HIV COVID-19

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

  • Text
  • PDF
Abstract

Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.

Authors

Ane Ogbe, Matthew Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari, Anna Bara, Samantha Broadhead, Anthony Brown, Helen Brown, Federica Cappuccini, Paola Cinardo, Wanwisa Dejnirattisai, Katie J. Ewer, Henry Fok, Pedro M. Folegatti, Jamie Fowler, Leila Godfrey, Anna L. Goodman, Bethany Jackson, Daniel Jenkin, Mathew Jones, Stephanie Longet, Rebecca A. Makinson, Natalie G. Marchevsky, Moncy Mathew, Andrea Mazzella, Yama F. Mujadidi, Lucia Parolini, Claire Petersen, Emma Plested, Katrina M. Pollock, Thurkka Rajeswaran, Maheshi N. Ramasamy, Sarah Rhead, Hannah Robinson, Nicola Robinson, Helen Sanders, Sonia Serrano, Tom Tipton, Anele Waters, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Gavin R. Screaton, Alan Winston, Adrian V.S. Hill, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Sarah Fidler, Julie Fox, Teresa Lambe, John Frater

×

Figure 7

Cross-reactive humoral immune responses among Beta CoVs.

Options: View larger image (or click on image) Download as PowerPoint
Cross-reactive humoral immune responses among Beta CoVs.
(A–C) Antibody ...
(A–C) Antibody titres against (A) SARS-CoV, (B) MERS-CoV, and (C) HKU1 spike proteins measured at day 0 (baseline) and day 182 (6 months after vaccination) in HIV+ participants. (D–F) Correlation between baseline antibody titres for SARS-CoV-2 and (D) SARS-CoV-1, (E) MERS-CoV, and (F) HKU1 spike protein at baseline. (G) Phylogenetic tree showing relationship between coronaviruses. Correlation was performed via Spearman’s rank correlation coefficient, and comparison of 2 time points within the same group was done by Wilcoxon matched-pairs signed-rank test. ****P ≤ 0.0001. Dotted lines in A and B indicate cut-off points determined for each SARS-CoV-2 antigen based on prepandemic sera + 3 SD. n = 48–54 for HIV+ volunteers. Data are shown as median ± IQR.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts